Advanced search
1 file | 381.72 KB Add to list

Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062

(2011) EUROPEAN JOURNAL OF CANCER. 47(15). p.2322-2330
Author
Organization
Keywords
PACLITAXEL, CHEMOTHERAPY, EPIRUBICIN, CARCINOMA, TOPOTECAN, REGIMEN, PREVIOUSLY UNTREATED PATIENTS, Toxicity, Survival, Amrubicin, Small cell lung cancer, CYCLOPHOSPHAMIDE, VINCRISTINE, TRIAL

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 381.72 KB

Citation

Please use this url to cite or link to this publication:

MLA
O’Brien, Mary ER, Krzystof Konopa, Paul Lorigan, et al. “Randomised Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin Versus Cisplatin Etoposide as First-line Treatment in Patients with Extensive Stage Small Cell Lung Cancer: EORTC 08062.” EUROPEAN JOURNAL OF CANCER 47.15 (2011): 2322–2330. Print.
APA
O’Brien, M. E., Konopa, K., Lorigan, P., Bosquee, L., Marshall, E., Bustin, F., Margerit, S., et al. (2011). Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062. EUROPEAN JOURNAL OF CANCER, 47(15), 2322–2330.
Chicago author-date
O’Brien, Mary ER, Krzystof Konopa, Paul Lorigan, Lionel Bosquee, Ernest Marshall, Frederique Bustin, Sabine Margerit, et al. 2011. “Randomised Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin Versus Cisplatin Etoposide as First-line Treatment in Patients with Extensive Stage Small Cell Lung Cancer: EORTC 08062.” European Journal of Cancer 47 (15): 2322–2330.
Chicago author-date (all authors)
O’Brien, Mary ER, Krzystof Konopa, Paul Lorigan, Lionel Bosquee, Ernest Marshall, Frederique Bustin, Sabine Margerit, Christian Fink, Jos A Stigt, Anne Marie C Dingemans, Baktiar Hasan, Jan Van Meerbeeck, and Paul Baas. 2011. “Randomised Phase II Study of Amrubicin as Single Agent or in Combination with Cisplatin Versus Cisplatin Etoposide as First-line Treatment in Patients with Extensive Stage Small Cell Lung Cancer: EORTC 08062.” European Journal of Cancer 47 (15): 2322–2330.
Vancouver
1.
O’Brien ME, Konopa K, Lorigan P, Bosquee L, Marshall E, Bustin F, et al. Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062. EUROPEAN JOURNAL OF CANCER. 2011;47(15):2322–30.
IEEE
[1]
M. E. O’Brien et al., “Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062,” EUROPEAN JOURNAL OF CANCER, vol. 47, no. 15, pp. 2322–2330, 2011.
@article{2043921,
  author       = {O'Brien, Mary ER and Konopa, Krzystof and Lorigan, Paul and Bosquee, Lionel and Marshall, Ernest and Bustin, Frederique and Margerit, Sabine and Fink, Christian and Stigt, Jos A and Dingemans, Anne Marie C and Hasan, Baktiar and Van Meerbeeck, Jan and Baas, Paul},
  issn         = {0959-8049},
  journal      = {EUROPEAN JOURNAL OF CANCER},
  keywords     = {PACLITAXEL,CHEMOTHERAPY,EPIRUBICIN,CARCINOMA,TOPOTECAN,REGIMEN,PREVIOUSLY UNTREATED PATIENTS,Toxicity,Survival,Amrubicin,Small cell lung cancer,CYCLOPHOSPHAMIDE,VINCRISTINE,TRIAL},
  language     = {eng},
  number       = {15},
  pages        = {2322--2330},
  title        = {Randomised phase II study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer: EORTC 08062},
  url          = {http://dx.doi.org/10.1016/j.ejca.2011.05.020},
  volume       = {47},
  year         = {2011},
}

Altmetric
View in Altmetric
Web of Science
Times cited: